Research › Fact Sheets › BIIB

BIOGEN INC.

LISTEDNASDAQ

SYMBOLBIIB

SIC2836

STATE OF INC.DE

FISCAL YEAR ENDSDecember 31

CIK875045

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)	Amount	%
Total debt	6,287	25.6
Stockholders' equity	18,257	74.4
Total capitalization	24,544	100.0

147,637,117 shares outstanding at 27 April 2026 (cover page of the 10-Q filed 29 April 2026).

LONG-TERM DEBT 12/31/25

($ millions)	Amount
Long-term debt, incl. current maturities	6,287
Current maturities	0

CAPITAL STOCK 12/31/25

Common shares authorized	1,000,000,000
Common shares issued	170,500,000
Treasury shares	23,800,000
Par or stated value per share ($)	0.0005
Outstanding at 4/27/26	147,637,117

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	–	–
2024	–	–
2023	–	–
2022	–	–
2021	–	–

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware. Formerly known as BIOGEN IDEC INC. (to 20 March 2015); BIOGEN IDEC INC (to 25 April 2007); IDEC PHARMACEUTICALS CORP / DE (to 12 November 2003); IDEC PHARMACEUTICALS CORP / CA (to 14 February 1997).

BUSINESS: Classified by the SEC under Standard Industrial Classification 2836, Biological Products, (No Diagnostic Substances). Large accelerated filer. Principal executive office: 225 Binney Street, Cambridge, MA 02142. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/31/25	12/31/24	12/31/23
Revenues	9,891	9,676	9,836
Cost of revenues	2,404	2,310	2,533
Research and development	1,779	1,980	2,445
Selling, general and administrative	2,434	2,404	2,550
Depreciation and amortization	780	673	495
Interest expense	268	250	247
Income before income taxes	1,556	1,906	1,297
Income taxes	264	274	135
Net income	1,293	1,632	1,161
Earned per share, diluted ($)	8.79	11.18	7.97
Dividends per share ($)	–	–	–

CONSOLIDATED BALANCE SHEET

($ millions)	12/31/25	12/31/24
Receivables, net	1,342	1,405
Inventories	2,168	2,460
Total current assets	8,974	7,457
Property, plant and equipment, net	3,055	3,181
Goodwill	6,491	6,479
Total assets	29,440	28,049
Total current liabilities	3,349	5,529
Total liabilities	11,183	11,333
Total liabilities and equity	29,440	28,049

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/31/25	9,891	–	1,293	13.1	8.79	–	2,205	154	2,051	29,440	11,183	6,287	18,257	7.1	0.34
12/31/24	9,676	–	1,632	16.9	11.18	–	2,876	154	2,722	28,049	11,333	6,296	16,716	9.8	0.38
12/31/23	9,836	–	1,161	11.8	7.97	–	1,547	277	1,270	26,845	12,045	6,938	14,799	7.8	0.47
12/31/22	10,173	–	3,047	29.9	20.87	–	1,384	240	1,144	24,554	11,166	6,281	13,398	22.7	0.47
12/31/21	10,982	2,841	1,556	14.2	10.40	–	3,640	258	3,382	23,877	12,918	6,274	10,896	14.3	0.58
12/31/20	13,445	4,550	4,001	29.8	24.80	–	4,230	425	3,805	24,619	13,933	7,426	10,700	37.4	0.69
12/31/19	14,378	7,043	5,888	41.0	31.42	–	7,079	514	6,564	27,234	13,895	4,459	13,343	44.1	0.33
12/31/18	13,453	5,889	4,431	32.9	21.58	–	6,188	771	5,417	25,289	12,257	5,936	13,040	34.0	0.46
12/31/17	12,274	5,346	2,539	20.7	11.92	–	4,551	867	3,684	23,653	11,054	5,935	12,613	20.1	0.47
12/31/16	11,449	5,152	3,703	32.3	16.93	–	4,587	616	3,971	22,877	10,748	6,513	12,140	30.5	0.54

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

BIOGEN INC.
CIK 875045 · EIN 33-0112644

PRINCIPAL OFFICE:

225 Binney Street, Cambridge, MA 02142
Tel.: 6176792000

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

2836 · Biological Products, (No Diagnostic Substances)

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 6 February 2026

FORMER NAMES:

BIOGEN IDEC INC.; BIOGEN IDEC INC; IDEC PHARMACEUTICALS CORP / DE

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

7/29/26	10-Q	period 6/30/26
7/29/26	8-K	period 7/29/26
7/1/26	8-K	period 7/1/26
6/10/26	8-K	period 6/9/26
5/14/26	8-K	period 5/14/26
4/29/26	10-Q	period 3/31/26
4/29/26	8-K	period 4/29/26
4/28/26	DEF 14A	period 6/9/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/6/26) · 10-K FY2024 (filed 2/12/25) · 10-K FY2023 (filed 2/14/24) · 10-K FY2022 (filed 2/15/23) · 10-K FY2021 (filed 2/3/22) · 10-K FY2020 (filed 2/3/21) · 10-K FY2019 (filed 2/6/20) · 10-K FY2018 (filed 2/6/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.